Vascular Biogenics (VBLT) Posts Earnings Results, Misses Estimates By $0.03 EPS
Vascular Biogenics (NASDAQ:VBLT) posted its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.03), MarketWatch Earnings reports.
Shares of VBLT opened at $1.15 on Wednesday. Vascular Biogenics has a 12-month low of $1.10 and a 12-month high of $8.75. The company has a debt-to-equity ratio of 0.01, a quick ratio of 10.45 and a current ratio of 10.45. The stock has a market cap of $40.19 million, a P/E ratio of -3.11 and a beta of -1.25.
VBLT has been the topic of a number of recent analyst reports. HC Wainwright upgraded Vascular Biogenics from a “neutral” rating to a “buy” rating and set a $3.00 price objective on the stock in a research note on Monday, October 15th. Zacks Investment Research upgraded Vascular Biogenics from a “hold” rating to a “buy” rating and set a $1.75 price objective on the stock in a research note on Thursday, August 23rd. Finally, Chardan Capital reiterated a “hold” rating and issued a $3.00 price objective on shares of Vascular Biogenics in a research note on Tuesday. Five equities research analysts have rated the stock with a hold rating and one has given a buy rating to the stock. Vascular Biogenics currently has an average rating of “Hold” and a consensus price target of $2.94.
ILLEGAL ACTIVITY NOTICE: This report was first posted by Daily Political and is the property of of Daily Political. If you are reading this report on another domain, it was stolen and republished in violation of international copyright law. The original version of this report can be read at https://www.dailypolitical.com/2018/11/21/vascular-biogenics-vblt-posts-earnings-results-misses-estimates-by-0-03-eps.html.
Vascular Biogenics Company Profile
Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer. The company's program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels.
Receive News & Ratings for Vascular Biogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics and related companies with MarketBeat.com's FREE daily email newsletter.